Express Pharma

MARCH 16, 2025

What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.

Biosimilars 110

Biosimilars Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies 110

European Pharmaceutical Review

NOVEMBER 25, 2024

percent between 2024 and 2032. An increasing trend of outsourcing boosts growth of the market as pharmaceutical companies are utilising advanced testing capabilities and optimising their drug development processes. percent market share between 2024 and 2032, based on the forecast by Straits Research.

Drug Development 52

Drug Development Biosimilars Compounding Pharmaceutical Companies 52

European Pharmaceutical Review

JUNE 7, 2024

Pharmaceutical companies ask themselves this question before embracing the latest technologies because every innovation comes with both opportunities and risks. According to recent estimates, the opportunity from generative AI alone could produce up to $110 billion in annual value across the pharmaceutical industry value chain.

Health and Personal Care Stores 113

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Drug Development 113

European Pharmaceutical Review

AUGUST 9, 2023

As a highly selective BTK inhibitor, remibrutinib “has the potential to be a first-in-class, oral treatment for people living with CSU whose symptoms are refractory despite use of antihistamines,” stated Dr Shreeram Aradhye, President of Global Drug Development and Chief Medical Officer at Novartis.

Immunization 94

Immunization Immunity Pharmaceutical Companies Pharmaceutical Companies 94

Pharmaceutical Technology

MAY 23, 2023

The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. The proposed changes aim to reduce the time between new drug launches in the 27 EU markets and the entry of generic competitors into the market.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Packaging 52

pharmaphorum

MARCH 10, 2022

“This trend will continue in the near future with a steady increase in market demand over the coming years, alongside further development in cell and gene therapies,” says Magnelli. Accordingly, pharmaceutical companies are expected to up their investment in this area, both in terms of production infrastructure and expertise.”.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunization 98

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2024 [cited 2024May]. BMB Reports. 2017;50(3):111–6.

Drug Development 103

Drug Development Biosimilars Documentation Compounding 103

pharmaphorum

APRIL 19, 2022

Drug development is never a swift process, and RudaCure still has many steps to take to bring its drugs to global markets. But thanks to a strong foundation of exciting, novel drug candidates and the help of investors, partners, and accelerators, Kim believes they’re well on their way. Conclusion.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Drug Development 52

European Pharmaceutical Review

JANUARY 13, 2025

3 Encouragingly, there are many examples of the life sciences sector seeking to embrace sustainable drug development; reconciling the drive for innovation with the need to reduce waste and emissions produced during the R&D process, as well as throughout the product lifecycle. 2024; 85: 1-9. Internet] The Aerosol Society.

Packaging 52

Packaging Community Pharmacies Documentation Pharmaceutical Companies 52

European Pharmaceutical Review

FEBRUARY 1, 2024

What are the top three trends impacting the cardiovascular drug development space today? Beyond clinical trials, what other challenges are impacting pharmaceutical companies today? You see very few cardiovascular companies as a startup biotech, and there are reasons for that.

Documentation 97

Documentation Diabetes Pharmaceutical Companies Pharmaceutical Companies 97

European Pharmaceutical Review

APRIL 10, 2024

EAPs should therefore be considered both important and complementary to clinical trials, allowing pharmaceutical companies to gain a better understanding of how patients respond to treatments outside of a controlled, clinical environment. cited 2024Feb]. cited 2024Feb]. Available from: [link] Malard F, Loschi M, Huynh A, et al.

Immunization 95

Immunization Immunity Chemotherapy Diabetes 95

Pharmaceutical Technology

SEPTEMBER 26, 2022

These highlight the parent company’s focus on innovative and high-value drug development. Sandoz has faced and may in the future face strong competition from other generic and biosimilar pharmaceutical companies, which aggressively compete for market share, including through significant price competition.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

Drug Patent Watch

DECEMBER 11, 2024

This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Your Drugs Development Stage The stage of your drug development is a critical factor in selecting a CDMO.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Communication Drug Development 98

European Pharmaceutical Review

JANUARY 23, 2025

For example, 2024 saw companies trying to tap innovation at an earlier point in the development cycle, and the industry turned away from the big deals for de-risked assets that characterised 2023. For large pharmaceutical companies, 2024 may have been a digestion year, as they integrate the acquisitions made the previous year.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Drug Development 59

STAT

OCTOBER 16, 2024

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You

Pharmaceutical Companies 283

Pharmaceutical Companies Pharmaceutical Companies Drug Development 283